Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06833 Sinco Pharmaceuticals
0.285
-0.015-5.00%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Assets
Current assets
Inventory
-54.77% 45.25M -74.74% 61.27M -62.7% 100.04M -6.44% 242.56M
Accounts receivable
-21.99% 232.58M -63.09% 213.6M 208.04% 298.14M 1784.36% 578.69M
Advance deposits and other receivables
50.86% 282.97M 668.87% 313.04M 1408.64% 187.57M -62.71% 40.71M
Cash and equivalents
71.05% 456.71M 126.8% 326.05M 116.59% 267M -34.58% 143.77M
Secured deposit
563.71% 116.91M -- 55.02M -- 17.62M -- --
Total current assets
30.34% 1.13B -3.65% 968.98M 73.82% 870.37M 60.68% 1.01B
Non-current assets
Property, plant and equipment
16.97% 217.56M 10.42% 207.87M -3.29% 185.99M -4.44% 188.25M
Investment property
-2.73% 6.41M -2.7% 6.5M -6.45% 6.59M -6.36% 6.68M
Advance payment
3764.12% 101.01M -78.77% 169K 287.83% 2.61M 56.69% 796K
Intangible assets
164900% 16.5M -- -- -69.7% 10K -51.11% 22K
Goodwill
-- 66.54M -- -- -- -- -- --
Deferred tax assets
355.66% 2.9M 33.13% 860K 287.8% 636K -10.4% 646K
Special items of non-current assets
18.15% 58.03M -3.08% 48.39M 10349.79% 49.11M 4696.73% 49.93M
Total non-current assets
91.44% 468.94M 7.09% 263.79M 22.05% 244.95M 19.32% 246.33M
Total assets
43.76% 1.6B -1.54% 1.23B 59.01% 1.12B 50.42% 1.25B
Liabilities
Current liabilities
Accounts payable
80.49% 568.28M -39.61% 422.93M 93.13% 314.86M 133.08% 700.32M
Tax payable
-82.15% 4.31M -41.7% 12.83M 913.09% 24.15M 93.64% 22M
Other payables and accrued expenses
-64.38% 46.46M -67.01% 53.42M -46.71% 130.42M 38.56% 161.95M
Bank loans and overdrafts
0.91% 200.84M 167.12% 208.32M -- 199.02M -58.4% 77.99M
Financial lease liabilities-current liabilities
220% 1.63M -47.83% 384K -5.03% 510K -27.98% 736K
Special items of current liabilities
-24.79% 26.2M -0.2% 27.75M -51.65% 34.84M -27.93% 27.81M
Total current liabilities
20.45% 847.72M -26.76% 725.64M 22.03% 703.79M 51.08% 990.79M
Net current assets
72.11% 286.69M 1529.44% 243.34M 319.23% 166.58M 149.97% 14.93M
Total assets less current liabilities
83.62% 755.63M 94.11% 507.13M 229.96% 411.53M 47.98% 261.26M
Non-current liabilities
Long-term bank loan
-0.51% 131.97M 4247.27% 132.24M -- 132.65M -- 3.04M
Long-term accounts payable
-- -- -- -- -14.64% 39.05M -- --
Financial lease liabilities-non-current liabilities
6334.68% 7.98M -- -- -46.09% 124K 138.31% 367K
Deferred tax liability
-- 2.48M -- -- -- -- -- --
Special items of non-current liabilities
-- 16.94M -- -- -- -- -- 93.42M
Total non-current liabilities
-7.25% 159.36M 36.57% 132.24M 273.72% 171.82M -25.66% 96.83M
Total liabilities
15.01% 1.01B -21.12% 857.88M 40.62% 875.61M 38.37% 1.09B
Total assets less total liabilities
148.75% 596.27M 127.99% 374.89M 204.42% 239.71M 255.2% 164.43M
Total equity and non-current liabilities
83.62% 755.63M 94.11% 507.13M 229.96% 411.53M 47.98% 261.26M
Equity
Share capital
20.59% 164K 11.03% 151K 0% 136K 0% 136K
Reserve
148.82% 596.11M 126.84% 374.74M 201.29% 239.57M 251.01% 165.2M
Legal reserve
148.82% 596.11M 126.84% 374.74M 201.29% 239.57M 251.01% 165.2M
Shareholders' Equity
148.75% 596.27M 126.74% 374.89M 200.95% 239.71M 250.29% 165.34M
Non-controlling interest
-- -- -- -- -- -- 0% -908K
Total equity
148.75% 596.27M 127.99% 374.89M 204.42% 239.71M 255.2% 164.43M
Total equity and total liabilities
43.76% 1.6B -1.54% 1.23B 59.01% 1.12B 50.42% 1.25B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--Ernst & Young accounting firm--Ernst & Young accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO: Xiangbin Huang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...